Dr. Andrew Schiff joined Aisling Capital in September of 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, PowerVision, and ZELTIQ Aesthetics, and as a Board observer of Zavante Therapeutics. He is a longtime supporter and Board member of the Visiting Nurse Service of New York. Dr. Schiff received his MD from Cornell University Medical College, his MBA from Columbia University, and his BS with honors in Neuroscience from Brown University.